Evaluation of CYP3A4-Mediated Interactions of Gefitinib and Erlotinib Using Physiologically-Based Pharmacokinetic Models
Drug Targets and Therapeutics · 31.03.2026 · 5 (1) · 12-23
DOI: 10.58502/dtt.26.0006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Targets and Therapeutics, erschienen am 31.03.2026. Verfasst von Yearin Jun und 3 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
Zitieren
APA
Jun, Y., Lee, S. J., Bae, S. K., & Bae, S. H. (2026). Evaluation of CYP3A4-Mediated Interactions of Gefitinib and Erlotinib Using Physiologically-Based Pharmacokinetic Models. Drug Targets and Therapeutics, 5(1), 12-23. https://doi.org/10.58502/dtt.26.0006
Vancouver
Jun Y, Lee SJ, Bae SK, Bae SH. Evaluation of CYP3A4-Mediated Interactions of Gefitinib and Erlotinib Using Physiologically-Based Pharmacokinetic Models. Drug Targets and Therapeutics. 2026;5(1):12-23. doi:10.58502/dtt.26.0006
BibTeX
@article{Jun2026,
author = {Jun, Yearin and Lee, So Jin and Bae, Soo Kyung and Bae, Soo Hyeon},
title = {Evaluation of CYP3A4-Mediated Interactions of Gefitinib and Erlotinib Using Physiologically-Based Pharmacokinetic Models},
journal = {Drug Targets and Therapeutics},
year = {2026},
volume = {5},
number = {1},
pages = {12--23},
doi = {10.58502/dtt.26.0006}
}
EUVIMED